Navigation Links
Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
Date:12/9/2013

SEATTLE, Dec. 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is administered orally and has been previously shown to induce complete remissions as monotherapy in relapsed or refractory AML. Researchers presented the findings from this combination study today for the first time at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition held December 7–10 in New Orleans, La.

"Treatment outcomes for older patients with newly diagnosed AML remain poor," said John Pagel, M.D., Ph.D., Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Associate Professor, Medical Oncology Division, University of Washington School of Medicine; and Principal Investigator in the tosedostat first-line AML/MDS trial. "This is the first time that tosedostat has been given in a front-line setting in combination with low intensity therapy. The complete response rates and median survival observed in previously untreated older patients with AML is promising and appears to be worthy of further clinical investigation." 

The Phase 2 trial was designed to test the efficacy of tosedostat in combination with low intensity therapy for older patients with previously untreated AML or high-risk MDS not considered candidates for standard intensive therapy. This presentation reported on the results of 26 patients (median age was 69) enrolled in t
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... YORK, England , July 30, 2015 /PRNewswire/ ... Regenix" or "The Group") the regenerative medical devices ... position within the post-acute wound care market as ... approval for DermaPure® under Medicare administrator, First Coast ... Florida , Puerto ...
(Date:7/30/2015)... Laboratories, Inc. (NASDAQ: IDXX ) today reported revenues ... an increase of 6% compared to the prior year ... reduced reported revenue growth by 7%. Normalized organic revenue ... by strong growth in the Companion Animal Group ("CAG") ... for the quarter, an increase of 9% compared to ...
(Date:7/29/2015)... July 30, 2015  Astellas today announced topline ... the efficacy and safety of intravenous (IV) and ... under development for adults with candidemia and other ... study demonstrated that the trial did not meet ... response in isavuconazole-treated patients at the end of ...
Breaking Medicine Technology:Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5
... PRINCETON, N.J., Feb. 7, 2011 Pharmasset, Inc. (Nasdaq: ... committed to discovering, developing, and commercializing novel drugs to ... highlights for the quarter ended December 31, 2010. ... the quarter ended December 31, 2010 compared to $0.3 ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today ... update on the progress of Sangamo,s ZFP Therapeutic® development programs ... pm ET on Monday, February 14, 2011 at the 13th ... in New York City. The presentation will be ...
Cached Medicine Technology:Pharmasset Reports Fiscal First Quarter 2011 Financial Results 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 3Pharmasset Reports Fiscal First Quarter 2011 Financial Results 4Pharmasset Reports Fiscal First Quarter 2011 Financial Results 5Pharmasset Reports Fiscal First Quarter 2011 Financial Results 6Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference 2
(Date:7/30/2015)... ... July 30, 2015 , ... Ross A. Clevens, ... of Medicine as Assistant Professor of Plastic Surgery. This is Dr. Clevens’ second ... worked closely with the university, developing a strong presence and a valuable mentoring program ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Using the ... suicide and teach people more effective ways to prevent and manage major depression. , ... react fast enough, so people fall through the cracks and die needlessly everyday,” says ...
(Date:7/30/2015)... ... July 30, 2015 , ... Between 2012 and 2014 ... Health News Florida on June 17th. Those untreated heroin use disorders share ... prevent the spread of dirty needles throughout the community. Ultimately Florida’s HIV infection rates ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Association of ... announcement of the reinstitution of National Prescription Drug Take-Back Days. The 10th event ... AM to 2:00 PM local time. On the 26th, the DEA, with the ...
(Date:7/30/2015)... ... July 30, 2015 , ... InventHelp, a leading ... designed a personal-care device that makes it easy to apply lotion or medication to ... need for assistance when applying lotion or medication to the back, and provides thorough ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... , SACRAMENTO, Calif., Dec. 17 Just in time for ... tighten their firm grip on drunk drivers today by and declaring ... $8 million in grant funding to 148 law enforcement agencies for ... California Office of Traffic Safety (OTS) will fund more than 2,500 ...
... , , Some of NYC,s most iconic ... oil phase out by 2020 , http://www.edf.org/dirtybuildings , ... pollution is created by burning the dirtiest heating oils available in only one ... report released today by Environmental Defense Fund . As a ...
... , , , ... Alliance for,Improved Nutrition released today its 2008-2009 Annual Report. ... malnutrition in,high-burden countries. GAIN,s national food fortification projects are,reaching ... million,women and young children. "Our attention to measuring the ...
... ... General Hospital project that used a novel communication tool to improve health outcomes among ... Care Safety Net Institute. , ... (Vocus) December 17, 2009 -- A UCSF/San Francisco General Hospital project that ...
... ... her options for birth – capturing all her wishes and preferences in a birth plan ... she wants. Her birth plan does not match her provider’s practice style. , ... Silver Spring, MD (Vocus) December 17, 2009 ...
... ... funding needed for continued success , ... Washington, DC (PRWEB) December 17, 2009 -- According to the World Health ... third of affected countries included in the study have witnessed reduction in malaria cases by ...
Cached Medicine News:Health News:California Announces 2010 as The Year of the Checkpoint 2Health News:California Announces 2010 as The Year of the Checkpoint 3Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 2Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 3Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 4Health News:GAIN's Effectiveness in Reducing Malnutrition Confirmed in its New Annual Report 2Health News:SFGH Project for Diabetes Patients Wins Award for Innovation, Quality 2Health News:SFGH Project for Diabetes Patients Wins Award for Innovation, Quality 3Health News:Who Should Deliver Your Baby? New Tool Helps Expectant Parents Choose Their Health Care Provider 2Health News:Who Should Deliver Your Baby? New Tool Helps Expectant Parents Choose Their Health Care Provider 3Health News:WHO World Malaria Report Shows Aid Efforts Are Working 2Health News:WHO World Malaria Report Shows Aid Efforts Are Working 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: